Facebook tracking pixel
C18.7
ICD-10-CM
Malignant Neoplasm of Sigmoid Colon

Find comprehensive information on Malignant Neoplasm of Sigmoid Colon, including ICD-10 code C18.7, clinical documentation requirements, staging, treatment options, and healthcare resources. This guide covers sigmoid colon cancer diagnosis, symptoms, prognosis, and pathology reports. Learn about medical coding best practices for malignant neoplasms, tumor markers, and relevant healthcare terminology for accurate documentation. Explore resources for patients and healthcare professionals regarding sigmoid colon cancer care.

Also known as

Sigmoid Colon Cancer
Sigmoid Colon Carcinoma

Diagnosis Snapshot

Key Facts
  • Definition : Cancerous growth in the sigmoid colon (part of the large intestine)
  • Clinical Signs : Rectal bleeding, abdominal pain, change in bowel habits, iron-deficiency anemia
  • Common Settings : Hospital, oncology clinic, surgical center, gastroenterology clinic

Related ICD-10 Code Ranges

Complete code families applicable to AAPC C18.7 Coding
C18

Malignant neoplasm of colon

Covers cancers specifically affecting the colon, including the sigmoid colon.

C19

Malignant neoplasm of rectosigmoid junction

Cancers located at the junction between the rectum and sigmoid colon.

C20

Malignant neoplasm of rectum

Cancers affecting the rectum, anatomically close to the sigmoid colon.

Z85

Personal history of malignant neoplasm

Used to document a past diagnosis of cancer, including sigmoid colon cancer.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the sigmoid colon neoplasm confirmed malignant?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Sigmoid colon cancer
Colon cancer NOS
Recurrent colon cancer

Documentation Best Practices

Documentation Checklist
  • Malignant neoplasm sigmoid colon diagnosis
  • ICD-10 C18.7 documentation requirements
  • Confirm diagnosis with pathology report
  • Document tumor size, location, and grade
  • Record TNM stage if available
  • Note any metastases and lymph node involvement

Coding and Audit Risks

Common Risks
  • Unspecified Site

    Coding C18.7 without laterality (C18.5, C18.6) when documented causes unspecified site issues, impacting reimbursement and data accuracy.

  • In Situ Overcoding

    Incorrectly coding in situ neoplasms (D01.0) as invasive (C18.x) leads to overstating severity, affecting cancer registry data and treatment plans.

  • Sequencing Issues

    Incorrect sequencing of sigmoid colon cancer with obstruction or perforation can lead to denied claims and inaccurate quality metrics.

Mitigation Tips

Best Practices
  • Code C18.7 for Malignant Neoplasm of Sigmoid Colon.
  • Document tumor size, location, and differentiation for accurate staging.
  • Ensure complete history, including family history of colon cancer.
  • Query physician for clarity if documentation is unclear or incomplete.
  • Follow established CDI guidelines for consistent coding and billing compliance.

Clinical Decision Support

Checklist
  • Confirm sigmoid colon location via imaging/endoscopy
  • Verify histology report: adenocarcinoma or other malignancy
  • Document TNM staging: size, nodes, metastasis
  • Assess for obstruction, perforation, or other complications
  • Review family history of colorectal cancer

Reimbursement and Quality Metrics

Impact Summary
  • Malignant Neoplasm Sigmoid Colon reimbursement: Coding accuracy impacts C18-C21 code assignment, affecting case mix index and hospital revenue.
  • Quality metrics: Accurate sigmoid colon cancer staging (TNM) crucial for quality reporting, impacting hospital performance scores.
  • Sigmoid colon cancer treatment documentation: Impacts accurate APR-DRG assignment, influencing reimbursement and quality metrics.
  • Timely abstracting and coding: Minimizes denials, optimizes sigmoid colon cancer patient care revenue cycle.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What are the most effective current treatment strategies for locally advanced malignant neoplasm of the sigmoid colon in elderly patients with comorbidities?

A: Treatment for locally advanced malignant neoplasm of the sigmoid colon in elderly patients with comorbidities requires a multidisciplinary approach and individualized treatment plans. While surgical resection remains the cornerstone of treatment when feasible, the extent of surgery (e.g., laparoscopic vs. open, segmental vs. subtotal colectomy) needs careful consideration based on patient frailty, comorbidities, and tumor characteristics. Neoadjuvant chemotherapy or chemoradiotherapy may be beneficial in downstaging the tumor and improving resectability. For patients deemed unfit for surgery, options include palliative chemotherapy, radiation therapy, or best supportive care. Consider implementing a comprehensive geriatric assessment to guide treatment decisions and optimize patient outcomes. Explore how prehabilitation strategies can enhance surgical tolerance and postoperative recovery in this population. Learn more about the role of minimally invasive surgery in managing sigmoid colon cancer in elderly patients.

Q: How can I differentiate between diverticulitis and sigmoid colon cancer during diagnostic workup, considering overlapping symptoms and radiological findings?

A: Differentiating diverticulitis and sigmoid colon cancer can be challenging due to overlapping symptoms like abdominal pain, changes in bowel habits, and rectal bleeding. While both conditions may present similar findings on CT scans, certain features can help distinguish them. For example, irregular bowel wall thickening, pericolonic fat stranding, and lymphadenopathy are more suggestive of malignancy. Colon cancer often presents with a distinct mass, whereas diverticulitis usually manifests as inflammation and bowel wall thickening. Ultimately, a definitive diagnosis relies on tissue biopsy obtained through colonoscopy or flexible sigmoidoscopy. For patients with inconclusive imaging, consider implementing carcinoembryonic antigen (CEA) testing as an adjunct, though it is not diagnostic on its own. Explore how advanced imaging techniques like MRI or PET/CT can aid in differentiating these conditions. Learn more about the value of multidisciplinary discussion in complex cases to optimize diagnostic accuracy.

Quick Tips

Practical Coding Tips
  • Code C18.7 sigmoid colon cancer
  • Document tumor specifics, stage
  • Confirm laterality, if applicable
  • Consider neoadjuvant therapy codes
  • Check for mets, code separately

Documentation Templates

Patient presents with complaints consistent with possible sigmoid colon cancer.  Symptoms include altered bowel habits, such as constipation, diarrhea, or a change in stool caliber,  rectal bleeding or blood in stool, abdominal pain or discomfort, unexplained weight loss, fatigue, and anemia.  Physical examination may reveal abdominal tenderness, palpable mass, or hepatomegaly.  Differential diagnosis includes diverticulitis, inflammatory bowel disease, irritable bowel syndrome, and polyps.  Diagnostic workup includes colonoscopy with biopsy, which confirmed the diagnosis of malignant neoplasm of the sigmoid colon.  The pathology report indicates adenocarcinoma.  Staging workup, including CT scan of the abdomen and pelvis, chest x-ray, and CEA levels, will be performed to determine the extent of disease.  The patient was counseled regarding treatment options, including surgical resection, chemotherapy, radiation therapy, and targeted therapy.  The patient understands the risks and benefits of each treatment modality and will follow up for further discussion and treatment planning with oncology and surgery.  ICD-10 code C18.7 and relevant CPT codes will be applied for billing purposes.  This case necessitates ongoing monitoring and follow-up care to assess treatment response, manage potential complications, and ensure optimal patient outcomes.  The patient's prognosis depends on the stage of the cancer and response to therapy.